OBJECTIVES: The purpose of this study is to evaluate the sensitivity and specificity of free circulating DNA (FCDNA) as a biomarker in patients suffering from colorectal cancer (CRC), investigating both its prognostic value correlated with stage of disease and its potential role in early recurrence diagnosis. METHODS: The quantification of plasma DNA was achieved through the use of real time quantitative polymerase chain reaction (PCR) amplification of the RNAse P gene. The study enrolled patients undergoing surgery for primary CRC, at different stages of disease; samples were collected before surgery and during follow-up examinations every 3 months after surgery. Data were statistically analyzed using Software Packages SPSS® for Windows. RESULTS: FCDNA was detectable in all pre-operative samples and the mean value was 47.8 ng/mL. FCDNA values increased progressively related to UICC stage of disease, although statistical significance was demonstrated only when comparing patients by pT stage. The analysis of postoperative samples showed a significant decrease of FCDNA quantity after radical surgery and in specific cases a rise preceding disease recurrence. CONCLUSIONS: This study shows that absolute quantification of FCDNA in CRC patients could have a prognostic value, being related to stage of disease, and could be used as potential tool for early detection of recurrences.
OBJECTIVES: The purpose of this study is to evaluate the sensitivity and specificity of free circulating DNA (FCDNA) as a biomarker in patients suffering from colorectal cancer (CRC), investigating both its prognostic value correlated with stage of disease and its potential role in early recurrence diagnosis. METHODS: The quantification of plasma DNA was achieved through the use of real time quantitative polymerase chain reaction (PCR) amplification of the RNAse P gene. The study enrolled patients undergoing surgery for primary CRC, at different stages of disease; samples were collected before surgery and during follow-up examinations every 3 months after surgery. Data were statistically analyzed using Software Packages SPSS® for Windows. RESULTS: FCDNA was detectable in all pre-operative samples and the mean value was 47.8 ng/mL. FCDNA values increased progressively related to UICC stage of disease, although statistical significance was demonstrated only when comparing patients by pT stage. The analysis of postoperative samples showed a significant decrease of FCDNA quantity after radical surgery and in specific cases a rise preceding disease recurrence. CONCLUSIONS: This study shows that absolute quantification of FCDNA in CRC patients could have a prognostic value, being related to stage of disease, and could be used as potential tool for early detection of recurrences.
Authors: Phillip J Hsu; Khushboo Singh; Ankit Dhiman; Hunter D D Witmer; Chuan He; Oliver S Eng; Daniel V T Catenacci; Mitchell C Posner; Kiran K Turaga Journal: JCO Precis Oncol Date: 2022-02
Authors: Nicholas Eastley; Aurore Sommer; Barbara Ottolini; Rita Neumann; Jin-Li Luo; Robert K Hastings; Thomas McCulloch; Claire P Esler; Jacqueline A Shaw; Robert U Ashford; Nicola J Royle Journal: Int J Mol Sci Date: 2020-06-24 Impact factor: 5.923
Authors: Jakub Styk; Gergely Buglyó; Ondrej Pös; Ádám Csók; Beáta Soltész; Peter Lukasz; Vanda Repiská; Bálint Nagy; Tomáš Szemes Journal: Cancers (Basel) Date: 2022-07-29 Impact factor: 6.575
Authors: Hariti Saluja; Christos S Karapetis; Susanne K Pedersen; Graeme P Young; Erin L Symonds Journal: Front Oncol Date: 2018-07-24 Impact factor: 6.244